Treatment-related associations of nucleus accumbens connectivity within mesocorticolimbic circuits in depression.

J Affect DisordJul 15, 2026 (epub)
Clinical ResearchPsychiatry

Hong Li, Junjie Wang, Junxia Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of fluoxetine and Shugan Jieyu Capsule on patients with mild-to-moderate depression, focusing on nucleus accumbens (NAc) connectivity. Sixty patients underwent treatment for 8 weeks, with both therapies showing significant symptom improvement. Notably, changes in NAc-rostral anterior cingulate cortex connectivity correlated with symptom improvement in the fluoxetine group.

Key findings

  • Both fluoxetine and SG treatments led to significant symptom improvement in depression.
  • Changes in NAc-rostral anterior cingulate cortex connectivity were significantly associated with symptom improvement in the fluoxetine group.
  • Remitters had stronger baseline connectivity between the NAc and ventral tegmental area compared to non-remitters.

Why it matters

Understanding the neural correlates of treatment response in depression can enhance personalized treatment strategies. This study highlights the potential of NAc connectivity as a biomarker for treatment efficacy.

Source

PubMed · PMID 42456817

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.